SCHEMBL5324679

SCHEMBL5324679

CCCC(C[C@H](N)C(=O)O)C(N)=O

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 7/20 0.78
GRIK2 Q13002 7/20 0.78
SLC1A2 P43004 6/20 0.78
SLC1A1 P43005 6/20 0.78
SLC1A3 P43003 5/20 0.78
CHRM1 P11229 1/20 0.52
AKR1A1 P14550 1/20 0.52
CHRM3 P20309 1/20 0.52
HTR2A P28223 1/20 0.52
HTR2C P28335 1/20 0.52
ADRA1A P35348 1/20 0.52
HRH1 P35367 1/20 0.52
DRD3 P35462 1/20 0.52
SLC6A3 Q01959 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC2 Q92769 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
SLC7A5 Q01650 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20838572 0.88 SLC1A2 (1.00) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL1039720 0.88 SLC1A2 (1.00) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL5281450 0.88 SLC1A2 (1.00) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL1039722 0.88 SLC1A2 (1.00) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL23565818 0.85 SLC1A2 (0.67) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL5320933 0.84 SLC1A2 (0.60) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL5324268 0.83 SLC1A2 (0.76) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL27467303 0.83 SLC1A2 (0.76) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
Valpromide SCHEMBL5321742 0.82 SLC1A1 (0.58) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL6032395 0.82 SLC1A1 (0.57) GRIK1GRIK2SLC1A2SLC1A1SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 GRIK1 4162/4885GRIK2 4536/4885SLC1A2 4787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.